Favipiravir
Cost Effective Process Technology of Favipiravir Developed by CSIR Used by M/s Cipla Ltd.
Glenmark Announces Results of Phase 3 Clinical Trial of Favipiravir on COVID Patients
Glenmark’s Favipiravir is Different from Livealth Bio Pharma’s Livfavir
COVID-19 Drug By Glenmark Set for Market at Rs 103 Per Tablet After Getting DCGI Approval
Glenmark: Antiviral Favipiravir To Enter into Phase 3 of Clinical Trials